middle.news
How Alterity’s ATH434 Could Transform Treatment for Multiple System Atrophy
9:40am on Friday 31st of October, 2025 AEDT
•
Biotechnology
Read Story
How Alterity’s ATH434 Could Transform Treatment for Multiple System Atrophy
9:40am on Friday 31st of October, 2025 AEDT
Key Points
Positive Phase 2 trial results reinforce ATH434 efficacy at higher doses
Open-label study confirms treatment effects in advanced MSA patients
Independent analysis projects $2.4 billion peak sales opportunity worldwide
Cash balance of A$54.56 million with quarterly operating outflows of A$5.34 million
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Alterity Therapeutics (ASX:ATH)
OPEN ARTICLE